11572 | Humans |
6625 | Female |
4496 | Male |
4165 | Middle Aged |
4103 | Adult |
2787 | Aged |
2757 | Lymphedema (etiology) |
2542 | Animals |
1559 | Adolescent |
1368 | Lymphedema (therapy) |
1226 | Lymphedema (diagnosis) |
1178 | Child |
1153 | Lymphedema (surgery) |
1055 | Breast Neoplasms (surgery) |
955 | Lymphedema (pathology) |
911 | Lymphedema (complications) |
869 | Aged, 80 and over |
852 | Treatment Outcome |
803 | Elephantiasis, Filarial (epidemiology) |
777 | Lymphedema (diagnostic imaging) |
771 | Leg |
682 | Child, Preschool |
666 | Follow-Up Studies |
653 | Lymphedema (physiopathology) |
634 | Arm |
616 | Diagnosis, Differential |
596 | Lymphedema |
585 | Lymphography |
582 | Elephantiasis, Filarial (prevention & control) |
566 | Elephantiasis, Filarial (drug therapy) |
549 | Chronic Disease |
523 | Elephantiasis, Filarial (parasitology) |
507 | Retrospective Studies |
506 | Time Factors |
489 | Risk Factors |
489 | Infant |
484 | Young Adult |
470 | Breast Neoplasms (complications) |
462 | Elephantiasis, Filarial (immunology) |
456 | Lymph Node Excision (adverse effects) |
436 | Prevalence |
423 | Mastectomy (adverse effects) |
421 | Lymphedema (prevention & control) |
412 | Quality of Life |
410 | Breast Neoplasms (pathology) |
400 | Syndrome |
382 | Lymphatic Metastasis |
377 | Lymphedema (genetics) |
377 | Lymphedema (epidemiology) |
360 | Lymph Node Excision |
350 | Breast Neoplasms (therapy) |
344 | Axilla |
342 | Prospective Studies |
338 | Postoperative Complications |
337 | Elephantiasis, Filarial (diagnosis) |
336 | Wuchereria bancrofti |
336 | Prognosis |
323 | Combined Modality Therapy |
321 | Surveys and Questionnaires |
319 | Breast Neoplasms (radiotherapy) |
312 | Elephantiasis, Filarial (transmission) |
308 | Lymphedema (drug therapy) |
308 | Diethylcarbamazine (therapeutic use) |
307 | Mastectomy |
303 | Neoplasm Staging |
302 | Lymphedema (congenital) |
301 | Mice |
299 | Lymph Nodes (pathology) |
299 | Filaricides (therapeutic use) |
295 | Bandages |
292 | Wuchereria bancrofti (isolation & purification) |
288 | Elephantiasis |
282 | Wuchereria bancrofti (immunology) |
278 | Infant, Newborn |
248 | Physical Therapy Modalities |
245 | Radionuclide Imaging |
231 | Skin Neoplasms (pathology) |
231 | Lymphatic System (surgery) |
216 | Cross-Sectional Studies |
210 | Severity of Illness Index |
208 | India (epidemiology) |
208 | Disease Models, Animal |
206 | Lower Extremity |
204 | Lymphatic System (pathology) |
200 | Methods |
199 | Lymphoscintigraphy |
199 | Incidence |
199 | Drainage |
198 | Leg (blood supply) |
197 | Antigens, Helminth (immunology) |
196 | Lymphedema (psychology) |
193 | Lymph Node Excision (methods) |
192 | Lymphatic System (physiopathology) |
181 | Skin (pathology) |
181 | Postoperative Complications (etiology) |
180 | Pressure |
178 | Sensitivity and Specificity |
178 | Age Factors |
177 | Radiotherapy (adverse effects) |
176 | Dogs |
172 | Lymphedema (rehabilitation) |
172 | Elephantiasis (etiology) |
170 | Tomography, X-Ray Computed |
170 | Recurrence |
169 | Veins (surgery) |
169 | Lymphatic System (physiology) |
168 | Edema (etiology) |
166 | Microsurgery (methods) |
166 | Lymph Nodes (surgery) |
165 | Lymphedema (nursing) |
164 | Elephantiasis, Filarial (pathology) |
163 | Lymphatic Vessels (surgery) |
163 | Diethylcarbamazine (administration & dosage) |
161 | Elephantiasis, Filarial (blood) |
158 | Biopsy |
157 | Elephantiasis, Filarial (complications) |
152 | Magnetic Resonance Imaging |
151 | Radiography |
150 | Reproducibility of Results |
150 | Filaricides (administration & dosage) |
149 | Rats |
145 | Lymphography (methods) |
145 | Brugia (immunology) |
144 | Arm (pathology) |
143 | Extremities |
142 | Antigens, Helminth (blood) |
141 | Lymph Nodes (diagnostic imaging) |
140 | Enzyme-Linked Immunosorbent Assay |
139 | Ivermectin (therapeutic use) |
138 | Antibodies, Helminth (blood) |
137 | Skin Transplantation |
137 | Lymphedema (metabolism) |
136 | Ultrasonography |
135 | Edema |
134 | Case-Control Studies |
133 | Disease |
132 | Lymph (physiology) |
131 | Pregnancy |
131 | Leg (surgery) |
130 | Pedigree |
130 | Lymphatic Vessels (pathology) |
128 | Neoplasms (complications) |
126 | Surgical Flaps |
126 | Sentinel Lymph Node Biopsy |
126 | Exercise Therapy |
126 | Elephantiasis (pathology) |
125 | India |
124 | Microfilariae (isolation & purification) |
123 | Leg (pathology) |
121 | Drug Therapy, Combination |
119 | Insect Vectors (parasitology) |
119 | Brugia malayi (immunology) |
118 | Hemangiosarcoma (pathology) |
118 | Albendazole (therapeutic use) |
117 | Phenotype |
117 | Cohort Studies |
115 | Phlebography |
115 | Breast Neoplasms (psychology) |
114 | Massage |
114 | Lymphedema (classification) |
114 | Lymph Nodes (transplantation) |
111 | Filariasis (epidemiology) |
110 | Endemic Diseases |
109 | Patient Education as Topic |
109 | Elephantiasis (diagnosis) |
108 | Pilot Projects |
108 | Edema (diagnosis) |
107 | Postoperative Complications (prevention & control) |
107 | Microsurgery |
106 | Stockings, Compression |
106 | Risk Assessment |
106 | Postoperative Complications (epidemiology) |
106 | Drainage (methods) |
106 | Anastomosis, Surgical |
105 | Predictive Value of Tests |
104 | Transplantation, Autologous |
104 | Lymphedema (immunology) |
104 | Brugia |
102 | Survivors |
102 | Scrotum |
102 | Culex (parasitology) |
101 | Filariasis (immunology) |
101 | Elephantiasis (surgery) |
101 | Breast Neoplasms (rehabilitation) |
101 | Anti-Bacterial Agents (therapeutic use) |
101 | Anastomosis, Surgical (methods) |
100 | Sex Factors |
99 | Elephantiasis (epidemiology) |
99 | Anthelmintics (therapeutic use) |
98 | Immunohistochemistry |
98 | Health Knowledge, Attitudes, Practice |
97 | Microfilariae (immunology) |
97 | Carcinoma, Squamous Cell (surgery) |
96 | Wuchereria bancrofti (drug effects) |
96 | Survival Rate |
95 | Drug Administration Schedule |
94 | Sentinel Lymph Node Biopsy (adverse effects) |
94 | Postoperative Complications (therapy) |
94 | Compression Bandages |
92 | Leg (diagnostic imaging) |
91 | Lymphangiosarcoma (etiology) |
90 | Molecular Sequence Data |
90 | Age Distribution |
88 | Skin Neoplasms (surgery) |
88 | Microfilariae |
88 | Lymphangiosarcoma (pathology) |
88 | Immunoglobulin G (blood) |
87 | Uterine Cervical Neoplasms (surgery) |
87 | Neoplasm Recurrence, Local |
87 | Insect Vectors |
86 | Postoperative Care |
86 | Lymphatic Vessels (diagnostic imaging) |
85 | Melanoma (surgery) |
85 | Ivermectin (administration & dosage) |
85 | Breast Neoplasms (drug therapy) |
84 | Obesity (complications) |
84 | Acute Disease |
83 | Pain (etiology) |
83 | Genital Diseases, Male (surgery) |
83 | Double-Blind Method |
82 | Postoperative Complications (surgery) |
81 | Skin Neoplasms (etiology) |
81 | Longitudinal Studies |
81 | Edema (therapy) |
81 | Arm (surgery) |
81 | Antigens, Helminth (analysis) |
80 | Upper Extremity |
80 | Scrotum (surgery) |
80 | Mutation |
80 | Global Health |
80 | Gerbillinae |
79 | Skin Neoplasms (complications) |
79 | Randomized Controlled Trials as Topic |
79 | Lymphatic System (anatomy & histology) |
79 | Body Mass Index |
79 | Albendazole (administration & dosage) |
78 | Reconstructive Surgical Procedures (methods) |
78 | Postoperative Complications (diagnosis) |
78 | Breast Neoplasms (mortality) |
77 | Lymphangiogenesis (physiology) |
77 | Cells, Cultured |
77 | Axilla (surgery) |
76 | Rural Population |
76 | Electric Impedance |
76 | Disease Progression |
76 | Chyle |
75 | Wound Healing |
75 | Radiotherapy, Adjuvant (adverse effects) |
75 | Mastectomy (methods) |
74 | Vulvar Neoplasms (surgery) |
74 | Neoplasm Metastasis |
74 | Endemic Diseases (prevention & control) |
73 | Range of Motion, Articular |
73 | Hemangiosarcoma (etiology) |
73 | Elephantiasis (therapy) |
72 | Radiotherapy, Adjuvant |
72 | Lymphatic System |
72 | Feasibility Studies |
71 | Survival Analysis |
71 | Socioeconomic Factors |
71 | Models, Biological |
71 | Mastectomy, Segmental |
71 | Fatal Outcome |
71 | Adaptation, Psychological |
69 | Mice, Inbred C57BL |
69 | Elephantiasis, Filarial (therapy) |
69 | Culicidae (parasitology) |
69 | Coloring Agents |
69 | Breast Neoplasms (physiopathology) |
68 | Wuchereria bancrofti (genetics) |
68 | Lymphatic System (abnormalities) |
68 | Filariasis (complications) |
68 | Contrast Media |
68 | Breast Neoplasms (diagnosis) |
67 | Lower Extremity (pathology) |
67 | Eyelashes (abnormalities) |
66 | Skin Neoplasms (diagnosis) |
66 | Radiotherapy Dosage |
66 | Disease-Free Survival |
66 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
66 | Analysis of Variance |
65 | Rabbits |
65 | Penile Diseases (surgery) |
65 | Patient Compliance |
65 | Obesity, Morbid (complications) |
65 | Lymphedema (chemically induced) |
65 | Amino Acid Sequence |
64 | Rural Health |
64 | Lymphatic Vessels (physiology) |
64 | Lymphatic Vessels (metabolism) |
64 | Filariasis (drug therapy) |
64 | Activities of Daily Living |
63 | Lymphangiogenesis |
63 | Groin |
63 | Exercise |
62 | Wuchereria bancrofti (growth & development) |
62 | Indocyanine Green |
62 | Chemotherapy, Adjuvant |
62 | Arm (physiopathology) |
62 | Amputation |
61 | Vulvar Neoplasms (pathology) |
61 | Technetium |
61 | Logistic Models |
61 | Filariasis (diagnosis) |
61 | Equipment Design |
61 | Clothing |
60 | Venous Insufficiency (therapy) |
60 | Radiopharmaceuticals |
60 | Medical Records |
60 | Coumarins (therapeutic use) |
60 | Breast Neoplasms (diagnostic imaging) |
59 | Vascular Endothelial Growth Factor Receptor-3 (genetics) |
59 | Sentinel Lymph Node Biopsy (methods) |
59 | Self Care |
59 | Mice, Inbred BALB C |
59 | Filariasis (parasitology) |
59 | Diethylcarbamazine (adverse effects) |
58 | Venous Insufficiency (complications) |
58 | United Kingdom |
58 | Microscopy, Electron |
58 | Lymphatic Diseases (diagnostic imaging) |
58 | Antibodies, Helminth (immunology) |
57 | Survivors (psychology) |
57 | Practice Guidelines as Topic |
57 | Microfilariae (drug effects) |
57 | Lymphatic Vessels (physiopathology) |
57 | Edema (physiopathology) |
57 | Base Sequence |
57 | Arm (blood supply) |
56 | Sex Distribution |
56 | Anopheles (parasitology) |
55 | Morbidity |
54 | World Health Organization |
54 | United States |
54 | Physical Therapy Modalities (methods) |
54 | Lymphocyte Activation |
54 | Hemangiosarcoma (diagnosis) |
54 | Comorbidity |
54 | Arm (diagnostic imaging) |
53 | Population Surveillance |
53 | Nursing Assessment |
53 | Elephantiasis (complications) |
53 | Carcinoma, Squamous Cell (pathology) |
52 | Uterine Cervical Neoplasms (pathology) |
52 | Upper Extremity (pathology) |
52 | Scrotum (pathology) |
52 | Pleural Effusion (complications) |
52 | Penis (surgery) |
52 | Palliative Care |
52 | Multivariate Analysis |
52 | Magnetic Resonance Imaging (methods) |
52 | Lymphangiosarcoma (diagnosis) |
52 | Hand |
52 | Angiography |
51 | Nail Diseases (complications) |
51 | Mosquito Control (methods) |
51 | Melanoma (pathology) |
51 | Lymphedema (blood) |
51 | Exercise Therapy (methods) |
51 | Ethiopia |
51 | Attitude to Health |
50 | Wuchereria bancrofti (physiology) |
50 | Lymphatic Diseases (diagnosis) |
50 | Inguinal Canal |
50 | Hindlimb |
50 | Carcinoma (surgery) |
50 | Breast Neoplasms (epidemiology) |
49 | Neoplasms (therapy) |
49 | Leg Ulcer (etiology) |
49 | Clinical Trials as Topic |
49 | Abnormalities, Multiple (genetics) |
48 | Venous Insufficiency (diagnosis) |
48 | Social Support |
48 | Onchocerciasis (drug therapy) |
48 | Mastectomy, Radical |
48 | Lymph Nodes (blood supply) |
48 | Lipectomy |
48 | Elephantiasis, Filarial (physiopathology) |
48 | Elephantiasis, Filarial (diagnostic imaging) |
48 | Anthelmintics (administration & dosage) |
47 | Mastectomy, Radical (adverse effects) |
47 | Genital Neoplasms, Female (surgery) |
47 | Filariasis |
47 | Elephantiasis, Filarial (economics) |
47 | Developing Countries |
47 | Cellulitis (etiology) |
46 | T-Lymphocytes (immunology) |
46 | Surgical Flaps (blood supply) |
46 | Regression Analysis |
46 | Preoperative Care |
46 | Onchocerciasis (epidemiology) |
46 | Lymphatic Metastasis (pathology) |
46 | History, 20th Century |
45 | Technetium Tc 99m Sulfur Colloid |
45 | Skin (blood supply) |
45 | Program Evaluation |
45 | Penile Diseases (etiology) |
45 | Onchocerciasis (prevention & control) |
45 | Health Surveys |
45 | Genotype |
45 | Genetic Predisposition to Disease |
45 | Forkhead Transcription Factors (genetics) |
45 | Evidence-Based Medicine |
45 | Carcinoma, Ductal, Breast (surgery) |
44 | Lymphangioma (pathology) |
44 | Erysipelas (complications) |
44 | Enzyme-Linked Immunosorbent Assay (methods) |
44 | Endometrial Neoplasms (surgery) |
44 | Elephantiasis, Filarial (psychology) |
44 | Edema (pathology) |
44 | Edema (diagnostic imaging) |
44 | Brugia malayi (isolation & purification) |
44 | Algorithms |
43 | Uterine Cervical Neoplasms (radiotherapy) |
43 | Thrombophlebitis (complications) |
43 | Technetium Tc 99m Aggregated Albumin |
43 | Signal Transduction |
43 | Postoperative Period |
43 | Melanoma (secondary) |
43 | Lymphatic Diseases (complications) |
43 | Lymphangiogenesis (genetics) |
43 | Filaricides (pharmacology) |
43 | Filariasis (prevention & control) |
43 | Fibrosis |
43 | Brugia (isolation & purification) |
43 | Biopsy, Needle |
43 | Antibodies, Helminth (analysis) |
42 | Venous Insufficiency (physiopathology) |
42 | Tanzania (epidemiology) |
42 | Reoperation |
42 | Quality of Life (psychology) |
42 | Patient Care Team |
42 | Neoplasm Invasiveness |
42 | Lymphatic Vessels (embryology) |
42 | Lymphatic Metastasis (diagnosis) |
42 | Immunity, Cellular |
42 | Ethiopia (epidemiology) |
42 | Endothelial Cells (metabolism) |
42 | Dose-Response Relationship, Drug |
42 | Antineoplastic Agents (adverse effects) |
41 | Wuchereria bancrofti (pathogenicity) |
41 | Polymerase Chain Reaction |
41 | Mice, Knockout |
41 | Lymphatic Metastasis (diagnostic imaging) |
41 | Immunoglobulin G (immunology) |
41 | Cost of Illness |
40 | Thigh |
40 | Testicular Hydrocele (epidemiology) |
40 | Recombinant Proteins (immunology) |
40 | Penile Neoplasms (surgery) |
40 | Pelvis |
40 | Mosquito Control |
40 | Lymphatic Diseases (pathology) |
40 | Lower Extremity (surgery) |
40 | Diuretics (therapeutic use) |
40 | Anthropometry |
40 | Adenocarcinoma (surgery) |
39 | Vascular Endothelial Growth Factor C (metabolism) |
39 | Skin Diseases (pathology) |
39 | Risk |
39 | Regional Blood Flow |
39 | Reference Values |
39 | Qualitative Research |
39 | Posture |
39 | Postoperative Complications (diagnostic imaging) |
39 | Patient Satisfaction |
39 | Pain Measurement |
39 | Lymphedema (parasitology) |
39 | Lymphangitis (etiology) |
39 | Hysterectomy |
39 | Health Status |
39 | Filaricides (adverse effects) |
39 | Evaluation Studies as Topic |
39 | Erysipelas (etiology) |
39 | Cats |
39 | Brugia (growth & development) |
39 | Aedes (parasitology) |
39 | Adipose Tissue (pathology) |
38 | Wuchereria (immunology) |
38 | Vascular Endothelial Growth Factor Receptor-3 (metabolism) |
38 | Thrombophlebitis (diagnosis) |
38 | Surgical Procedures, Operative |
38 | Saphenous Vein (surgery) |
38 | Radiation Injuries (etiology) |
38 | Neoplasm Recurrence, Local (pathology) |
38 | Malaria (prevention & control) |
38 | Lymphedema (veterinary) |
38 | Haiti (epidemiology) |
38 | Filariasis (pathology) |
38 | Disease Vectors |
38 | China (epidemiology) |
37 | Sarcoma, Kaposi (pathology) |
37 | Public Health |
37 | Postoperative Complications (physiopathology) |
37 | Organ Size |
37 | Mice, Transgenic |
37 | Massage (methods) |
37 | Ivermectin (adverse effects) |
37 | Brugia malayi (genetics) |
37 | Blotting, Western |